Tissue expression of MMP-9, TIMP-1, RECK, and miR338-3p in prostate gland: can it predict cancer?

Autor(es):Mostrar menos -

de Moraes, Rodolfo Pacheco ^[1] ; Pimenta, Ruan ^{[2, 1]} ; Mori, Fernando Noboru Cabral ^[1] ; dos Santos, Gabriel Arantes ^{[2, 1]} ; Viana, Nayara Izabel ^[1] ; Guimaraes, Vanessa Ribeiro ^[1] ; de Camargo, Juliana Alves ^[1] ; Moreira-Leite', Katia Ramos ^[1] ; Srougi, Miguel ^{[2, 1]} ; Nahas, William Carlos ^[3] ; Reis, Sabrina T. ^[1]

Afiliação do(s) autor(es)

^[1] Fac Med Sao Paulo FMUSP, Lab Med Invest LIM55, Urol Dept, Sao Paulo - Brazil

^[2] DOr Inst Res & Educ IDOR, Sao Paulo - Brazil

^[3] Univ Sao Paulo, Inst Canc Estado Sao Paulo ICESP, Sao Paulo - Brazil

• Tipo de documento: Artigo Científico
• Fonte: MOLECULAR BIOLOGY RESEARCH COMMUNICATIONS; v. 10, n. 4, p. 149-156, DEC 2021.
• Citações Web of Science: 0

Resumo

Prostate cancer is the most frequent malignancy affecting men worldwide. Due to the low sensitivity and specificity of the prostate-specific antigen test and the digital rectal exam as screening modalities, several alternatives are being studied. This study aimed to evaluate the application of MMP-9 and its regulators (TIMP-1, RECK, and miR-338-3p) as diagnostic and prognostic indicators of prostate cancer. A total of 134 randomly selected patients under investigation for prostate cancer submitted to a transrectal ultrasound-guided prostate biopsy were enrolled in the study; of these, 61 were positive for the disease (cases), and 73 were negative (control group). The tissue samples were further analyzed by gene and miR-338-3p expression analysis using qRT-PCR (one randomly selected fragment of each patient). Approximately 58% of the patients with prostate cancer presented MMP9 upregulation, while 73%, 65%, and 69% downregulated IMP-1, RECK, and miR-338-3p, respectively. MiR-338-3p was expressed at lower levels in patients with PSA concentrations exceeding 20 ng/mL (p=0.045) and abnormal DRE (p=0.006), while the RECK was more expressed in patients with abnormal DRE (p=0.01). We found that most patients with prostate cancer overexpressed MMP-9; on the other hand, most of them underexpressed TIMP-1, RECK, and miR-338-3p. MiR-338-3p presented as a possible predictor of poor prognosis. Further studies are warranted to evaluate these biomarkers as prognosis factors better. (AU)

• Processo FAPESP: 17/17489-3 - O papel dos marcadores MMP-9, TIMP-1, RECK no diagnóstico e prognóstico do câncer de próstata
• Beneficiário: Fernando Noboru Cabral Mori
• Modalidade de apoio: Bolsas no Brasil - Iniciação Científica